Results 131 to 140 of about 30,248 (245)
Loops with Transitive Automorphisms
, 1996 It is shown that isotopic loops with transitive automorphism groups are in fact isomorphic. A classification of loops with transitive automorphism groups is given.
Drisko, Arthur A.
core +1 more source
On transitive and fully transitive abelian p-groups
, 1996 It is a long standing problem of A.L.S. Corner as to whether there exists a non-transitive fully transitive Abelian p-group with finite Ulm subgroups. The principal result of this paper shows that no such group exists for a special class of p-groups if ...
Goldsmith, Brendan, Carroll, D.
core +1 more source
The cerebral palsy directed acyclic graph: A structural causal model of aetiology
Developmental Medicine &Child Neurology, EarlyView.The first international cerebral palsy directed acyclic graph (CP‐DAG) maps over 100 nodes and 370 links across biological, clinical, and social domains, offering a unified causal framework to guide research and identify knowledge gaps. Abstract Aim To describe the development of the initial version of the cerebral palsy (CP) directed acyclic graph ...
Shona Goldsmith +9 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Introduction Pharmacokinetic data suggest a potential dose‐dependent effect of sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitors on surrogate markers of efficacy, but the impact of SGLT‐2 inhibitor dose on renal and cardiovascular outcomes remains uncertain.
Elias John Elenjickal +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The approval of new pharmacotherapies for metabolic dysfunction‐associated steatohepatitis (MASH) presents a critical need for value assessment. We evaluated the cost‐effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2–F3 fibrosis.
Ali A. Abdeen +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami +2 more
wiley +1 more source